Shu Fu Pai

Gao Chen, Qian Li, Junli Chen, Fei Huang, Chunjun Qin, Xianya He

Abstract read

In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gao ChenDepartment of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.

Qian LiDepartment of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.

Junli ChenDepartment of Medical Records, Zhongjiang County Second People's Hospital Deyang 618107, Sichuan, China.

Fei HuangDepartment of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.

Chunjun QinDepartment of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.

Xianya HeDepartment of Infection, Deyang People's Hospital Deyang 618000, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical efficacy of Shu Fu Pai

methodsA retrospective analysis was conducted on 289 patients with liver cirrhosis and hypoalbuminemia who were admitted to Deyang People's Hospital between April 2021 and April 2023. Among them, 148 patients treated with Shu Fu Pai

resultsAfter treatment, there was a significant improvement in liver function, serum albumin level, Child-Pugh score, inflammatory markers, and coagulation function in both groups (all P=0.001). However, no significant difference was found in the peripheral blood indicators between the two groups (P>0.05). Also, there was no significant difference in complications between the two groups (P=0.194). Logistic regression analysis showed that age, pre-treatment serum albumin level, disease type, and abnormal liver function markers were independent factors affecting the treatment outcome of hypoalbuminemia, and treatment regimen was not an influencing factor.

conclusionShu Fu Pai

Indexed as

clinical efficacyhuman albuminHypoalbuminemialiver cirrhosisShu Fu Pai® Protein Short Peptides Beverage

Identifiers

PMID37854233

PMCPMC10579008

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.